Form 4: Tango Therapeutics Director Boosts Stake with New Equity and Options

Alexis Borisy, a Director at Tango Therapeutics, has acquired 6,250 restricted stock units and 37,500 stock options, signaling continued confidence in the company's future.

Summary

• Alexis Borisy, a Director of Tango Therapeutics, Inc. (TNGX), acquired 6,250 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025, at a price of $0.
• These RSUs will vest in their entirety on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders, contingent on Mr. Borisy's continuous service.
• Mr. Borisy also acquired 37,500 stock options on June 5, 2025, with an exercise price of $3.51 per share and a price of $0 for the option itself.
• These stock options will vest and become exercisable in 12 substantially equal monthly installments over one year, with the first vesting date on July 5, 2025, also subject to continuous service.
• Following these transactions, Mr. Borisy beneficially owns 17,500 shares of Common Stock and 37,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of additional equity and options by a director is generally viewed as a positive signal, indicating confidence in the company's future performance and alignment of interests with shareholders.

Positives

• The acquisition of additional equity (RSUs and stock options) by a director indicates strong confidence in the company's future prospects and valuation.
• The vesting schedules for both the RSUs and stock options incentivize the director's long-term commitment and alignment with shareholder interests.

Future Outlook

The vesting schedules for the acquired restricted stock units and stock options extend into 2026 and 2025 respectively, indicating a continued commitment from the director to the company's long-term performance and growth.

Industry Context

This Form 4 filing reflects an insider transaction, which is a routine disclosure in the biotechnology and pharmaceutical industry. Insider buying, particularly by a director, is often viewed positively as it suggests management's belief in the company's future prospects, which is a common signal investors look for in growth-oriented sectors like biotech.

Stakeholder Impact

• Shareholders may view this insider acquisition as a positive indicator of management's belief in the company's value and future growth, potentially increasing investor confidence.

Next Steps

• Vesting of 6,250 Restricted Stock Units on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders.
• Monthly vesting of 37,500 stock options over one year, commencing July 5, 2025.

Key Dates

Recommendation

Keywords

Tango Therapeutics, TNGX, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director, Equity Acquisition, Beneficial Ownership